GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A2884 Doxazosin MesylateSummary: α1-adrenergic receptor antagonist
-
A8521 SilodosinSummary: α1-adrenoceptor antagonist
-
A8474 Mirabegron (YM178)Target: adrenoceptorSummary: Selective β3-adrenoceptor agonist
-
B1986 NedaplatinSummary: DNA synthesis inhibitor
-
B1328 Terbutaline SulfateSummary: Selective β2-adrenergic receptor agonist
-
B1357 Dexmedetomidine HClSummary: Highly selective and potent alpha-2 adrenoceptor agonist
-
B1343 Phenoxybenzamine HClSummary: Adrenergic receptor antagonist
-
B1355 Cisatracurium BesylateTarget: AcetylcholineSummary: Neuromuscular-blocking drug
-
B1344 Phenylephrine HClSummary: Selective α1-adrenergic receptor agonist
-
B6552 CGP 20712 dihydrochlorideTarget: adrenoceptorSummary: β1 antagonist,highly potent and selective